Aclipse is developing a portfolio of potential disease-modifying drugs targeting a broad range of neuromuscular diseases.
M102, a dual NRF2/HSF1 activator shown to slow disease progression in a TDP43 model and promote motor neuron survival in a patient-derived iAstrocyte model, to enter Phase 1 trials in ALS in Q1 2025 with potential additional motor neuron protection applications in Friedreich’s Ataxia, Parkinson’s Disease, SMA and TBI.
M107, an anti-inflammatory drug shown to promote M2 macrophages and target the underlying causes of gastroparesis, a large and underserved market with a major upside driven by soaring GLP-1 drug uptake, to enter a Phase 2 gastroparesis trial in mid-2025.
